BioSpace News Archive

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022.

Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid, Bo Cumbo, President and Chief Executive Officer of AavantiBio, and Carl Morris, PhD, Chief Scientific Officer of Solid, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 10:30 a.m. ET.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present in a fireside chat at the virtual BTIG Ophthalmology Day on November 29, 2022 at 12:30 PM ET.

Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® in anti-PD1 failed melanoma.

Akari Therapeutics, Plc today announced that the company will participate in the Ophthalmology Day at BTIG on November 29, 2022.

scPharmaceuticals Inc. today announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share.

Applied UV, Inc. today announced its Board of Directors has authorized the cash dividend to holders of Applied UV’s 10.5% Series A Cumulative Perpetual Preferred Stock.

OcuTerra Therapeutics, Inc. today announced the company’s participation in two upcoming investor conferences.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022.

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA ® Versus IMBRUVICA ® in Late-Breaking Oral Session at ASH 2022.